References
- 1. LI L-S, LIU Z-H, Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004; 66(3): p. 920–923.
- 2. REICH HN, TROYANOV S, SCHOLEY JW, CATTRAN DC, Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12): p. 3177–3183.
- 3. BARBOUR SJ, REICH HN, Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012; 59(6): p. 865–873.
- 4. BARBOUR S, REICH H, An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018; 27(3): p. 214–220.
- 5. CATTRAN DC, COPPO R, COOK HT, FEEHALLY J, ROBERTS IS, TROYANOV S, et al., The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5): p. 534–545.
- 6. TRIMARCHI H, BARRATT J, CATTRAN D, COOK H, COPPO R, HAAS M, et al., IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Kidney Int. 2016;91:1014–1021
- 7. CATTRAN D, COPPO R, COOK H, FEEHALLY J, ROBERTS I, TROYANOV S, et al., Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76: p. 534–545.
- 8. SOARES MF, An update on pathology of IgA nephropathy. J Bras Nephrol.2016; 38(4): p. 435–440.
- 9. BELLUR SS, LEPEYTRE F, VOROBYEVA O, TROYANOV S, COOK HT, ROBERTS IS, et al., Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int. 2017; 91(1): p. 235–243.
- 10. TRIMARCHI H, BARRATT J, CATTRAN DC, COOK HT, COPPO R, HAAS M, et al., Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017; 91(5): p. 1014–1021.
- 11. HAAS M, VERHAVE JC, LIU Z-H, ALPERS CE, BARRATT J, BECKER JU, et al., A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017; 28(2): p. 691–701.
- 12. RADHAKRISHNAN J, CATTRAN DC, The KDIGO practice guideline on glomerulonephritis: reading between the (guide) lines—application to the individual patient. Kidney Int. 2012; 82(8): p. 840–856.
- 13. CATTRAN DC, FEEHALLY J, COOK HT, LIU ZH, FERVENZA FC, MEZZANO SA, et al., Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012; 2(2): p. 139–274.
- 14. KOBAYASHI Y, HIKI Y, FUJII K, KUROKAWA A, TATENO S, Moderately proteinuric IgA nephropathy: prognostic prediction of individual clinical courses and steroid therapy in progressive cases. Nephron. 1989; 53(3): p. 250–256.
- 15. TSUNODA R, USUI J, HOSHINO J, FUJII T, SUZUKI S, TAKAICHI K, et al., Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study. BMC Nephrol. 2018; 19(1): p. 222.
- 16. COPPO R, TROYANOV S, BELLUR S, CATTRAN D, COOK HT, FEEHALLY J, et al., Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86(4): p. 828–836.
- 17. ALAMARTINE E, SAURON C, LAURENT B, SURY A, SEFFERT A, MARIAT C, The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol, 2011; 6:2384–2388
- 18. KATAFUCHI R, NINOMIYA T, NAGATA M, MITSUIKI K, HIRAKATA H, Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011; 6(12): p. 2806–2813.
- 19. LV J, SHI S, XU D, ZHANG H, TROYANOV S, CATTRAN DC, et al., Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62(5): p. 891–899.
- 20. STANGOU M, PAPASOTIRIOU M, XYDAKIS D, OIKONOMAKI T, MARINAKI S, ZERBALA S, et al., IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology. Clin Kidney J. 2017; 11(1): p. 38–45.
- 21. MAIXNEROVA D, REILY C, BIAN Q, NEPRASOVA M, NOVAK J, TESAR V, Markers for the progression of IgA nephropathy. J Nephrol. 2016; 29(4): p. 535–541.
- 22. ABE K, MIYAZAKI M, KOJI T, FURUSU A, SHIOSHITA K, TSUKASAKI S, et al., Intraglomerular synthesis of complement C3 and its activation products in IgA nephropathy. Nephron. 2001; 87(3): p. 231–239.
- 23. MONTINARO V, GESUALDO L, RANIERI E, MONNO R, GRANDALIANO G, SCHENA FP, Renal cortical complement C3 gene expression in IgA nephropathy. J Am Soc Nephrol. 1997; 8(3): p. 415–425.
- 24. POZZI C, Treatment of IgA nephropathy. J Nephrol. 2016; 29(1): p. 21–25.
- 25. RAUEN T, EITNER F, FITZNER C, SOMMERER C, ZEIER M, OTTE B, et al., Intensive supportive care plus immunosuppression in IgA nephropathy. N Eng J Med. 2015; 373(23): p. 2225–2236.
- 26. YOON C-Y, CHANG TI, KANG EW, LIM BJ, KIE JH, KEE YK, et al., Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy. Ann Med. 2017; 49(3): p. 217–229.
- 27. RUAN Y, CHEN W, LI Z, TANG X, LI J, YU X, et al., Role of immunosuppressive therapy and predictors of therapeutic effectiveness and renal outcome in IgA nephropathy with proteinuria. Arch Med Sci. 2015; 11: 332.
- 28. CHOI S, LEE D, JEONG K, MOON J, LEE S, LEE T, et al., Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers. Clin Nephrol. 2009; 72(5): p. 353–359.
- 29. BARTOSIK LP, LAJOIE G, SUGAR L, CATTRAN DC, Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001; 38(4): p. 728–735.
- 30. INKER LA, MONDAL H, GREENE T, MASASCHI T, LOCATELLI F, SCHENA FP, et al., Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016; 68(3): p. 392–401.